Parenteral Drug Association
Connecting People, Science and Regulation ®
by: Dr. Bettine Boltres , Danica Brown , Beth Haas , Marty Lipa , Rhonda Sundberg , and Joseph Thomas, PDA Knowledge Management Roadmap Team
by: Martin VanTrieste
by: Cecilia Pierobon
Egmont Semmler, Groninger & Co.
John Shabushnig, PhD, Insight Pharma Consulting, and Markus Lankers, PhD, rap.ID Particle Systems GmbH
Rebecca Stauffer, PDA
Brittany Cloud, Eurofins Lancaster Laboratories, Inc.
Lee Leichter, P/L Biomedical
By: Andy Fry, Team Consulting
Thomas R. Kreil, PhD, Global Pathogen Safety, Shire
Colleen Walson-Billin, Amgen
Yingying Liu, ECURAC, and Siegfried Schmitt, PAREXEL
Geert Vandenbossche, Novartis; Marc Besson, Sanofi; Gabriele Gori, GSK Vaccines; Jette Christensen, Novo Nordisk; Gerry Morris, Eli Lilly and Company
Riccardo Luigetti, EMA, Emer Cooke, EMA, Brendan Cuddy, EMA, Sebastien Goux, European Commission, and Ian Rees, MHRA
Hal Baseman, Marsha Hardiman, Walter Henkels and Mike Long, ValSource
PDA Post Approval Change: Innovation for Availability of Medicines (PAC iAM) Task Force
Crystal Mersh, Quality Executive Partners
John Godshalk, Biologics Consulting
Anders Vinther, PhD, Sanofi Pasteur